Online citations, reference lists, and bibliographies.
← Back to Search

Immune-based Mechanisms Of Cytotoxic Chemotherapy: Implications For The Design Of Novel And Rationale-based Combined Treatments Against Cancer

L. Bracci, G. Schiavoni, A. Sistigu, F. Belardelli
Published 2014 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Conventional anticancer chemotherapy has been historically thought to act through direct killing of tumor cells. This concept stems from the fact that cytotoxic drugs interfere with DNA synthesis and replication. Accumulating evidence, however, indicates that the antitumor activities of chemotherapy also rely on several off-target effects, especially directed to the host immune system, that cooperate for successful tumor eradication. Chemotherapeutic agents stimulate both the innate and adaptive arms of the immune system through several modalities: (i) by promoting specific rearrangements on dying tumor cells, which render them visible to the immune system; (ii) by influencing the homeostasis of the hematopoietic compartment through transient lymphodepletion followed by rebound replenishment of immune cell pools; (iii) by subverting tumor-induced immunosuppressive mechanisms and (iv) by exerting direct or indirect stimulatory effects on immune effectors. Among the indirect ways of immune cell stimulation, some cytotoxic drugs have been shown to induce an immunogenic type of cell death in tumor cells, resulting in the emission of specific signals that trigger phagocytosis of cell debris and promote the maturation of dendritic cells, ultimately resulting in the induction of potent antitumor responses. Here, we provide an extensive overview of the multiple immune-based mechanisms exploited by the most commonly employed cytotoxic drugs, with the final aim of identifying prerequisites for optimal combination with immunotherapy strategies for the development of more effective treatments against cancer.
This paper references
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1182/blood-2008-08-173914
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.
A. Soriani (2009)
10.2741/2692
Macrophage activation and polarization.
F. Martinez (2008)
10.1126/science.1208347
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
M. Michaud (2011)
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.
F. Bertolini (2003)
10.1158/1535-7163.MCT-08-0993
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Y. Kim (2009)
10.1038/jid.2012.444
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
A. Sevko (2013)
10.1038/sj.leu.2401529
Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome
G. Salomons (1999)
Regular dose of gemcitabine induces an increase in CD14[+] monocytes and CD11c[+] dendritic cells in patients with advanced pancreatic cancer
添田 敦子 (2010)
10.1016/j.immuni.2013.03.003
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.
Y. Ma (2013)
10.1158/0008-5472.CAN-10-2670
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
Bethany L. Mundy-Bosse (2011)
10.1002/ijc.23886
Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients
P. Nisticò (2009)
10.4049/jimmunol.180.12.7887
Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions1
E. Ullrich (2008)
Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.
A. Nowak (2002)
10.4049/jimmunol.166.11.6608
Cyclophosphamide Induces the Development of Early Myeloid Cells Suppressing Tumor Cell Growth by a Nitric Oxide-Dependent Mechanism1
B. Peláez (2001)
10.1016/j.it.2011.06.007
T helper 17 cell heterogeneity and pathogenicity in autoimmune disease.
K. Ghoreschi (2011)
10.4049/jimmunol.1003267
DNA Alkylating Therapy Induces Tumor Regression through an HMGB1-Mediated Activation of Innate Immunity
Jennifer L. Guerriero (2011)
10.1084/jem.20051511
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner
F. Ghiringhelli (2005)
10.3389/fonc.2013.00049
Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer
Yana G. Najjar (2013)
10.1593/NEO.121572
CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.
A. Boissonnas (2013)
10.1111/j.1365-2567.2010.03357.x
Anti‐tumour synergy of cytotoxic chemotherapy and anti‐CD40 plus CpG‐ODN immunotherapy through repolarization of tumour‐associated macrophages
I. Buhtoiarov (2011)
10.1007/BF00199239
Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer
I. Mackay (2004)
10.1158/0008-5472.CAN-11-1316
Prognostic and predictive impact of intra- and peritumoral immune infiltrates.
W. Fridman (2011)
10.1172/JCI1348
Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
E. Proietti (1998)
10.1158/0008-5472.CAN-05-0646
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.
M. Loeffler (2005)
10.1158/0008-5472.CAN-09-3175
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
J. Seeger (2010)
10.1158/0008-5472.CAN-09-1106
Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation.
H. Tanaka (2009)
10.1016/j.immuni.2011.02.012
Functional specialization of interleukin-17 family members.
Y. Iwakura (2011)
10.1007/BF00199368
Effect of chemotherapy on NK function in the peripheral blood of cancer patients
D. Braun (2004)
10.1172/JCI28833
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.
R. Amaravadi (2007)
10.1016/j.cellimm.2009.11.011
Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.
M. Salem (2010)
10.1158/0008-5472.CAN-09-1101
Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells.
H. Tanaka (2009)
10.1038/nature03884
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
S. Gasser (2005)
10.1007/s10495-008-0303-9
Immunogenic cell death modalities and their impact on cancer treatment
O. Kepp (2008)
10.1084/jem.20050915
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N. Casares (2005)
10.1007/s00262-002-0365-4
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor
Silvia Ferrari (2003)
10.1126/SCIENCE.1096645
Regulation of an ATG7-beclin 1 Program of Autophagic Cell Death by Caspase-8
L. Yu (2004)
10.1158/0008-5472.CAN-10-1316
Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition.
J. H. Fine (2010)
10.1093/annonc/mds647
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
C. Zielinski (2013)
10.1158/1078-0432.CCR-05-0883
Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity
E. Suzuki (2005)
10.1016/j.biomaterials.2012.10.004
Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages.
Spencer Park (2013)
10.1158/0008-5472.CAN-10-0118
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
A. Boni (2010)
10.1097/00001813-200311000-00010
Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells
A. Galetto (2003)
10.1158/0008-5472.CAN-05-0529
Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.
Y. Nefedova (2005)
10.1016/j.clim.2008.07.013
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.
L. Zhang (2008)
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
S. Onizuka (1999)
10.1158/1078-0432.CCR-10-0733
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
K. Kodumudi (2010)
10.1016/S1734-1140(09)70098-2
Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice.
K. Bryniarski (2009)
10.1371/journal.pone.0006982
Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth
R. G. van der Most (2009)
10.1007/s00262-009-0734-3
Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination
Vedran Radojcic (2009)
10.1038/nri3175
Coordinated regulation of myeloid cells by tumours
D. Gabrilovich (2012)
10.1111/j.1349-7006.2011.02158.x
Influence of chemotherapy on nitric oxide synthase, indole‐amine‐2,3‐dioxygenase and CD124 expression in granulocytes and monocytes of non‐small cell lung cancer
S. Sim (2012)
10.1002/ijc.27786
Impact of chemotherapeutic agents on the immunostimulatory properties of human 6‐sulfo LacNAc+ (slan) dendritic cells
R. Wehner (2013)
10.1038/nrc1613
Immunotherapy and chemotherapy — a practical partnership
R. Lake (2005)
10.4049/jimmunol.170.10.4905
Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1
A. Nowak (2003)
10.1158/2159-8274.CD-10-0028
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
D. DeNardo (2011)
10.1245/s10434-011-1906-x
The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma
T. Tsuchikawa (2011)
10.1186/1479-5876-9-216
Identification and manipulation of tumor associated macrophages in human cancers
M. Heusinkveld (2011)
10.1016/j.molonc.2011.11.005
Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy
E. Proietti (2012)
10.1038/nrd3626
The secret ally: immunostimulation by anticancer drugs
L. Galluzzi (2012)
CD8þ tumorinfiltrating T-cells are trapped in the tumor-dendritic cell
A Boissonnas (2013)
10.1089/152581603321210136
Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen.
L. Šefc (2003)
10.4049/jimmunol.1100040
The DNA Damage Response Induces IFN
Sabrina Brzostek-Racine (2011)
10.4049/jimmunol.0803773
In Vivo Sensitized and In Vitro Activated B Cells Mediate Tumor Regression in Cancer Adoptive Immunotherapy1
Q. Li (2009)
10.4049/jimmunol.1004163
Type I IFNs Control Antigen Retention and Survival of CD8α+ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming
Silvia Lorenzi (2011)
10.1016/0162-3109(93)90015-I
Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide.
J. Brooks-Kaiser (1993)
Sensitivity of clonogenic cells of human ovarian ascitic cancer to antitumor drugs.
Potapov Sl (1988)
10.1158/0008-5472.CAN-12-2225
Dose-dense chemotherapy improves mechanisms of antitumor immune response.
C. Chang (2013)
Sensitivity of clonogenic cells of human ovarian ascitic cancer to antitumor drugs.
S. L. Potapov (1988)
10.1002/1097-0215(20000715)87:2<253::AID-IJC17>3.0.CO;2-A
Cyclophosphamide enhances anti‐tumor effect of wild‐type p53‐specific CTL
M. P. Vierboom (2000)
10.3109/08923977909040546
Comparative effects of azathioprine, cyclophosphamide and frentizole on humoral immunity in mice.
S. Smith (1979)
10.1182/blood-2008-09-177360
Endogenous IL-17 contributes to reduced tumor growth and metastasis.
Ilona Kryczek (2009)
10.1172/JCI34333
Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.
P. Kim (2008)
10.1158/0008-5472.CAN-10-1259
Cyclophosphamide induces differentiation of Th17 cells in cancer patients.
S. Viaud (2011)
10.1158/1078-0432.CCR-06-1209
Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration
L. Bracci (2007)
10.1007/s00262-012-1343-0
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo
M. Tongu (2012)
10.1007/s00262-008-0523-4
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
C. Diaz-Montero (2008)
10.1097/CJI.0b013e3181b56af4
Administration of Cyclophosphamide Changes the Immune Profile of Tumor-bearing Mice
P. Liu (2010)
Differential effects of cytotoxic agents on hematopoietic progenitors.
L. Botnick (1981)
10.4049/jimmunol.0902309
Cyclophosphamide Induces Dynamic Alterations in the Host Microenvironments Resulting in a Flt3 Ligand-Dependent Expansion of Dendritic Cells
M. Salem (2010)
10.1016/0008-8749(87)90318-2
Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice.
D. A. Nikcevich (1987)
10.1182/BLOOD.V84.7.2221.BLOODJOURNAL8472221
Lymphocyte depletion during treatment with intensive chemotherapy for cancer.
C. Mackall (1994)
10.1634/theoncologist.2009-0141
Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
S. Agarwala (2010)
10.1182/blood-2009-11-253336
Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.
Zhi-Chun Ding (2010)
10.1172/JCI43656
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
W. Lesterhuis (2011)
10.1158/0008-5472.CAN-11-3380
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
J. C. Doloff (2012)
10.1084/JEM.194.6.823
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
R. P. Sutmuller (2001)
10.1182/BLOOD-2004-06-2410
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
M. E. C. Lutsiak (2005)
10.1002/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO;2-2
A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes
G. Cassinelli (2001)
10.1097/CJI.0b013e3182328569
Cancer Cells Containing Nanoscale Chemotherapeutic Drugs Generate Antiovarian Cancer-specific CD4+ T Cells in Peritoneal Space
J. Kim (2012)
10.1038/sj.bjc.6605465
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. Liu (2010)
10.1007/s00262-011-1012-8
Camouflage and sabotage: tumor escape from the immune system
I. Poschke (2011)
10.1172/JCI40269
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.
R. Ramakrishnan (2010)
10.1002/ijc.26181
Cetuximab ± chemotherapy enhances dendritic cell‐mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen‐specific cytotoxic T‐cell response in vitro
P. Correale (2012)
10.1158/0008-5472.CAN-10-4523
Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.
F. Moschella (2011)
10.1002/ijc.24500
Autophagy—A double‐edged sword in oncology
Anja Apel (2009)
10.4049/jimmunol.164.12.6166
M-1/M-2 Macrophages and the Th1/Th2 Paradigm1
C. Mills (2000)
10.1002/ijc.26219
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
B. Farsaci (2012)
10.1158/0008-5472.CAN-09-3690
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
J. Vincent (2010)
10.1016/J.IMLET.2005.06.011
Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.
Yuriy V. Shebzukhov (2005)
10.1038/nm1622
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
L. Apetoh (2007)
10.1007/s00262-011-1106-3
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Y. Ge (2011)
10.1038/onc.2009.356
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesnière (2010)
10.1158/0008-5472.CAN-10-1326
Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.
B. Palermo (2010)
10.1038/nrc3237
Combining immunotherapy and targeted therapies in cancer treatment
M. Vanneman (2012)
10.1111/j.1365-3083.2011.02514.x
CD4+Foxp3+ Regulatory T‐cell Impairment by Paclitaxel is Independent of Toll‐like Receptor 4
Y. Zhu (2011)
10.1101/gad.180331.111
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
T. Shree (2011)
10.1038/nm.2438
Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
V. Balachandran (2011)
10.1016/j.vaccine.2009.02.018
Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine.
E. Montero (2009)
10.1002/1097-0142(19910801)68:3<482::AID-CNCR2820680306>3.0.CO;2-9
The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer
B. Brenner (1991)
10.1097/CJI.0b013e31824b3a76
5-Fluorouracil and Interferon-&agr; Immunochemotherapy Enhances Immunogenicity of Murine Pancreatic Cancer Through Upregulation of NKG2D Ligands and MHC Class I
H. Khallouf (2012)
10.1158/1078-0432.CCR-08-1332
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
J. Ko (2009)
10.1158/0008-5472.CAN-11-0753
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.
S. Mattarollo (2011)
CD 4 þ Foxp 3 þ regulatory T - cell impairment by paclitaxel is independent of toll - like receptor 4
Y Zhu (2011)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1007/s002620100229
Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes
E. S. Bergmann-Leitner (2001)
10.4049/jimmunol.0900734
Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism1
G. Shurin (2009)
10.1126/SCIENCE.3489291
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
S. Rosenberg (1986)
10.1128/CVI.00292-09
Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model
T. Kim (2009)
10.1002/ijc.11243
Influence of drug‐induced apoptotic death on processing and presentation of tumor antigens by dendritic cells
S. Buttiglieri (2003)
10.1016/j.ejps.2009.08.009
Paclitaxel and immune system.
A. Javeed (2009)
10.1007/s00262-009-0671-1
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
C. Banissi (2009)
10.1002/IJC.2910550506
Chemotherapy‐induced differential changes in lymphocyte subsets and natural‐killer‐cell function in patients with advanced breast cancer
H. Sewell (1993)
: relationships with features at presentation , in vitro and in vivo drug response and long - term clinical outcome
L Galluzzi (1999)
10.1089/cbr.2011.1116
Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model.
J. Chen (2012)
10.1007/s00262-006-0225-8
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
F. Ghiringhelli (2006)
10.1158/0008-5472.CAN-10-2788
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis.
G. Schiavoni (2011)
10.3109/08923978109026424
Comparative effects of azathioprine, cyclophosphamide and frentizole on cellular immunity in mice.
S. Smith (1981)
10.1182/BLOOD.V95.6.2024
Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.
G. Schiavoni (2000)
10.1016/0008-8749(85)90242-4
Cyclophosphamide-induced suppressor cells in mice: suppression of the antibody response in vitro and characterization of the effector cells.
M. Segre (1985)
10.1007/s00262-001-0237-3
Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model
P. Matar (2001)
10.2174/156652411795976574
Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies.
L. Apetoh (2011)
Comparative study of cyclophosphamide, 6-mercaptopurine, azathiopurine and methotrexate. Relative effects on the humoral and the cellular immune response in the mouse.
I. Otterness (1976)
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
A. Eberhard (2000)
10.1038/cgt.2011.56
Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models
J. Predina (2011)
10.1182/blood-2009-11-251231
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.
T. Nakahara (2010)
10.1186/1479-5876-7-58
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
R. Kaneno (2009)
10.4049/jimmunol.175.2.820
Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro1
P. Correale (2005)
10.1016/j.humimm.2009.02.008
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation.
A. Mantovani (2009)
10.1179/joc.2007.19.6.716
Changes in Cellular Immunity during Chemotherapy for Primary Breast Cancer with Anthracycline Regimens
N. Wijayahadi (2007)
10.1038/nrm3115
Mitotic catastrophe: a mechanism for avoiding genomic instability
I. Vitale (2011)
Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.
D. Berd (1984)
10.1200/JCO.2001.19.4.1195
Redefining the target: chemotherapeutics as antiangiogenics.
K. Miller (2001)
10.1097/01.cji.0000211311.28739.e3
Defining the Ability of Cyclophosphamide Preconditioning to Enhance the Antigen-specific CD8+ T-cell Response to Peptide Vaccination: Creation of a Beneficial Host Microenvironment Involving Type I IFNs and Myeloid Cells
M. Salem (2007)
10.1038/nm.2999
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
M. Bruchard (2013)
Bcl - 2 family members in childhood acute lymphoblastic
GS Salomons



This paper is referenced by
10.1016/j.biopha.2020.110377
Chemo-immunotherapy with doxorubicin prodrug and erythrocyte membrane-enveloped polymer nano-vaccine enhances antitumor activity.
Yuling Bao (2020)
10.1016/j.actbio.2020.10.006
A 3D-printed biomaterials-based platform to advance established therapy avenues against primary bone cancers.
Christoph A. Lahr (2020)
10.3779/j.issn.1009-3419.2015.04.08
[Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer].
S. Zhang (2015)
10.1016/j.coi.2016.01.005
Combinatorial immunotherapy strategies for hepatocellular carcinoma.
M. Tagliamonte (2016)
10.1016/j.tcb.2014.11.006
Microenvironmental regulation of therapeutic response in cancer.
Florian Klemm (2015)
10.4172/1948-5956.1000281
Vaccine Therapy for Pancreatic Cancer: A Battle against Deadly Cancer
Dipesh Kumar Yadav (2014)
10.1002/anie.201800422
A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy.
N. Wang (2018)
10.20473/FMI.V55I1.12543
Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
Reta Anggraeni Widya (2019)
10.1016/j.jtbi.2019.03.002
Mathematical modeling of tumor-immune cell interactions.
Grace E Mahlbacher (2019)
10.1038/s41423-019-0341-y
Targeting innate sensing in the tumor microenvironment to improve immunotherapy
Zhida Liu (2019)
10.3390/cancers12030746
Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients
G. Mandili (2020)
10.1016/j.canlet.2020.09.014
Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers.
Maria Davern (2020)
10.4161/21624011.2014.955684
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
Henri-Alexandre Michaud (2014)
10.21037/pcm.2019.11.08
Non-small cell lung cancer PDL1 >50%—should we go single or combo?
Waleed Kian (2020)
10.3892/OL.2020.12170
Metronomic chemotherapy in non-small cell lung cancer.
Y. Shu (2020)
10.1007/s00262-019-02452-3
Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients
J. Ma (2020)
10.4155/fmc-2019-0100
A small cytotoxic peptide from frog elicits potent antitumor immunity to prevent local tumor growth and metastases.
X. Qiao (2019)
10.14639/0392-100X-2481
Knowing the tumour microenvironment to optimise immunotherapy
M. Merlano (2019)
10.1007/978-3-030-21477-7_4
Novel Methods to Overcome Acquired Resistance to Immunotherapy
Xianda Zhao (2019)
Synthèse et évaluation pharmacologique d’analogues préactivés de l’ifosfamide : prodrogues et nanoparticules à visée antitumorale
C. Skarbek (2017)
Current Concepts in the Use of Cisplatin: A Historical Perspective and Its Recent Advances in the Treatment of Non-Small Cell Lung Cancer
Mark A. D’Andrea (2019)
10.1136/jitc-2020-000916
Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
J. Delahousse (2020)
10.1186/s12967-020-02218-x
Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy
A. Mauriello (2020)
10.1002/med.21463
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights
Ping-Pin Zheng (2018)
10.3389/fimmu.2018.01357
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis
A. Alex (2018)
10.1056/NEJMoa1801005
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
L. Gandhi (2018)
10.1016/j.cellimm.2018.02.012
Inhibiting HSP90 prevents the induction of myeloid-derived suppressor cells by melanoma cells.
N. Janssen (2018)
IMMUNOLOGICAL SIGNATURE IN NAÏVE AND SUNITINIB-TREATED SOFT TISSUE SARCOMA PATIENTS: ROLE OF MYELOID CELLS
M. Tazzari (2014)
10.3389/fmicb.2019.02924
Trained Immunity for Personalized Cancer Immunotherapy: Current Knowledge and Future Opportunities
Joana R Lérias (2019)
10.3389/fimmu.2019.02121
Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses
R. Loyon (2019)
10.1007/978-3-319-29827-6_4
NK Cell Responses in Immunotherapy: Novel Targets and Applications
R. Pachynski (2016)
10.1586/14737140.2015.1059279
The importance of the tumor microenvironment in the therapeutic management of cancer
C. Pottier (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar